T TAYSHA GENE THERAPIES INC
| Market Cap | $1.26B |
| P/E Ratio | — |
| Forward P/E | -10.72 |
| Dividend Yield | — |
| Beta | 1.08 |
| 52W Range | $1.13 - $5.91 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $861.00K | 156,586 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 13 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Alam KamranCHIEF FINANCIAL OFFICER | Sale | 1,655 | $4.52 | $7.48K | 04 Feb 2026 | 06 Feb 2026 |
| Kamran AlamCHIEF FINANCIAL OFFICER | Sale | 1,655 | $4.52 | $7.48K | 04 Feb 2026 | 06 Feb 2026 |
| Nagendran SukumarPresident and Head of R&D | Sale | 26,918 | $4.61 | $124.09K | 26 Jan 2026 | 27 Jan 2026 |
| Nolan Sean P.Chief Executive Officer | Sale | 41,312 | $4.61 | $190.45K | 26 Jan 2026 | 27 Jan 2026 |
| Alam KamranCHIEF FINANCIAL OFFICER | Sale | 23,849 | $4.61 | $109.94K | 26 Jan 2026 | 27 Jan 2026 |
| Nolan Sean P.Chief Executive Officer | Sale | 136,789 | $4.75 | $649.75K | 23 Jan 2026 | 27 Jan 2026 |
| Nagendran SukumarPresident and Head of R&D | Sale | 89,132 | $4.75 | $423.38K | 23 Jan 2026 | 27 Jan 2026 |
| Alam KamranCHIEF FINANCIAL OFFICER | Sale | 78,968 | $4.75 | $375.10K | 23 Jan 2026 | 27 Jan 2026 |
| Nagendran SukumarPresident and Head of R&D | Sale | 200,000 | $4.71 | $942.00K | 12 Jan 2026 | 14 Jan 2026 |
| Nagendran SukumarPresident and Head of R&D | Sale | 260,047 | $4.51 | $1.17M | 01 Dec 2025 | 01 Dec 2025 |
| Sukumar NagendranPresident and Head of R&D | Sale | 260,047 | $4.51 | $1.17M | 01 Dec 2025 | 01 Dec 2025 |
| Nagendran SukumarPresident and Head of R&D | Sale | 110,125 | $4.75 | $523.09K | 28 Nov 2025 | 01 Dec 2025 |
| Sukumar NagendranPresident and Head of R&D | Sale | 110,125 | $4.75 | $523.09K | 28 Nov 2025 | 01 Dec 2025 |
Frequently Asked Questions
What is TSHA stock price today?
TAYSHA GENE THERAPIES INC (TSHA) is currently trading at $4.37. The stock has a 52-week range of $1.13 to $5.91 and a market capitalization of $1.26B.
Is TSHA a good stock to buy in 2026?
TAYSHA GENE THERAPIES INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +246.8%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling TSHA stock?
There have been 13 insider transactions for TSHA in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has TSHA stock performed over the past year?
TAYSHA GENE THERAPIES INC (TSHA) has returned +246.8% over the past 12 months. The stock traded between $1.13 and $5.91 during this period, and is currently at $4.37.
Which hedge funds own TSHA (TAYSHA GENE THERAPIES INC)?
1 tracked hedge funds currently hold TSHA in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is TSHA's market cap and valuation?
TAYSHA GENE THERAPIES INC (TSHA) has a market capitalization of $1.26B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is TSHA's revenue and profitability?
TAYSHA GENE THERAPIES INC reported revenue of $9.77M with net income of N/A and a profit margin of N/A. The stock has a beta of 1.08.
What sector is TSHA in and who are its biggest institutional holders?
TAYSHA GENE THERAPIES INC (TSHA) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.